SPECIAL NOTICE
A -- Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other Indications
- Notice Date
- 7/15/2022 6:36:47 AM
- Notice Type
- Special Notice
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- NIH National Cancer Institute Rockville MD 20850 USA
- ZIP Code
- 20850
- Response Due
- 7/25/2022 1:00:00 PM
- Point of Contact
- Randall Tiqui, Carrie Mills
- E-Mail Address
-
randall.tiqui@nih.gov, carrie.mills@nih.gov
(randall.tiqui@nih.gov, carrie.mills@nih.gov)
- Description
- Special Notice of Intent: RFP No. 75N91021R00003 Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other Indications Contracting Office Address Department of Health and Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI), Office of Acquisitions (OA), Riverside Five, 8490 Progress Drive, Suite 400, Frederick, MD 21701-4998. Note: This notice is related to the Pre-Solicitation Notice released on October 30, 2020 and Solicitation (as amended) posted under Notice ID 75N91021R00003. Description The Toxicology and Pharmacology Branch (TPB) of the Developmental Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) is responsible for obtaining and evaluating preclinical toxicology and pharmacology data on anti-cancer drugs and biologicals that have been approved for NCI discovery and development. The ultimate goal is to identify and characterize the toxicologic profile and pharmacokinetic properties of potential drug candidates and to support an Investigational New Agent Application (IND) or a Drug Master File (DMF) with the U.S. Food and Drug Administration.� As stated in the original solicitation, the objective of the �Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other Indications� contract will be to conduct toxicology studies that will be used in the preclinical development of drugs for patients with cancer and other diseases. The Government continues to anticipate that one award will result from any solicitation posted for this requirement, for services outlined in greater detail in the revised Statement of Work (SOW) attached to this notice. Request for Proposals No:� 75N91021R00003 has closed and is currently under review by the Government.� The purpose of this notice is to inform interested parties that NCI intends to revise the anticipated contract type from a Cost-Reimbursement Level of Effort (LOE) contract to a single-award Indefinite Delivery-Indefinite Quantity (IDIQ) contract.� The IDIQ contract is anticipated to have a period of performance and ordering period of approximately seven years.� Award is anticipated on or about September 15, 2022.� Task orders placed within the ordering period of the resultant base IDIQ contract may extend up to seven years beyond the end date of the base IDIQ contract period of performance/ordering period. We anticipate task orders issued against the IDIQ contract will be cost reimbursement type. While the base IDIQ contract will not have options, options/optional tasks may be included at the individual task order level. The overall period of performance, estimated number of awards, reimbursement mechanism, estimated contract value and primary tasks outlined in the Statement of Work remain substantively unchanged from the original solicitation. The change in contract type is related to changes in programmatic need and considered to be in the best interest of the Government and the Contractor.� Required revisions to the solicitation as a result of this change in contract type will be addressed during negotiations, in accordance with FAR 16.103(a). This notice is NOT a request for proposals, proposal abstracts, quotations, or capabilities statements and does not commit the Government to any contractual relationship.� It is to inform the public that the Government intends to change the anticipated contract type from a Cost-Reimbursement Level of Effort to a single award IDIQ and offer an opportunity for interested parties to provide input and/or respond.� Responses to this notice must be received by 4:00 PM EST, July 25, 2022 and submitted via email to randall.tiqui@nih.gov.� DISCLAIMER AND IMPORTANT NOTES: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. Responses to this notice will not be considered adequate responses to a solicitation. The NCI reserves the right to make a single award or no award at all to the solicitation referenced in this special notice. In addition, the solicitation referenced in this special notice may be amended or canceled as necessary to meet NCI requirements. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/7e6b1c2d6c25497bb368325ca134e265/view)
- Place of Performance
- Address: USA
- Country: USA
- Country: USA
- Record
- SN06390269-F 20220717/220715230116 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |